UPMC Hillman Cancer Center

SITC and the NCI Announce Fourth Year of Collaboration with the New AI in IO: Computational Immuno-oncology Webinar Series

Retrieved on: 
Friday, April 12, 2024
Medical school, Immunotherapy, Society, Bangladesh Technical Education Board, Chairperson, AI, DRSN, Series, MD, Doctor of Philosophy, National Cancer Institute, Research, Artificial intelligence, Intelligence, Computation, Science, NCI, SITC, Big data, IO, UPMC Hillman Cancer Center, Knowledge, Chair

MILWAUKEE, April 12, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce their collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, on the fourth Computational Immuno-oncology Webinar Series. This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO). As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".

Key Points: 
  • This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO).
  • As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".
  • This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO).
  • As such, the series has been rebranded to "AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series".

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors

Retrieved on: 
Thursday, February 15, 2024
Leukemia, Division, American Cancer Society, Doctor of Philosophy, Immunotherapy, UPMC Shadyside, Drug development, UPMC, Leukemia & Lymphoma Society, University, Patient, UPMC Hillman Cancer Center, Explainable artificial intelligence, Research, Cancer, Management

PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.

Key Points: 
  • PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.
  • Dusty Majumdar, PhD, CEO of PredxBio
    "We are thrilled and privileged to announce the appointment of Dr. Marks as the Chairman of PredxBio's Board of Directors," expressed Dusty Majumdar, PhD, CEO of PredxBio.
  • "I am honored to serve as Chairman of the Board of Directors at PredxBio," commented Dr. Marks.
  • Supported by over 20 peer-reviewed publications, 4000+ citations, and numerous patents, PredxBio contributes significantly to improving cancer care.

FEB. 6-7 LESS CANCER WORKSHOP LEADING THE CHARGE ON CANCER PREVENTION

Retrieved on: 
Wednesday, February 7, 2024
Multimedia, Public, Representative, Continuing medical education, UPMC Hillman Cancer Center, Free clinic, National Cancer Institute, Nursing, Goldroom, Rayburn House Office Building, Physician, Cancer, Medicine, University, Student, Service, Birth control

WASHINGTON, Feb. 7, 2024 /PRNewswire/ -- The launch of Less Cancer's Annual National Cancer Prevention Workshop took place on Tuesday, February 6 in the Gold Room of the Rayburn Building, bringing together physicians, scientists, legislators, students, educators and advocates to discuss the strides made in cancer prevention.

Key Points: 
  • The Warrenton, VA, based non-profit Less Cancer , celebrating 20 years,  has led the charge on cancer prevention, initiating the United States Bipartisan Congressional Cancer Prevention Caucus, National Cancer Prevention Day, and the National Cancer Prevention Workshop.
  • "We are so grateful for the bipartisan leadership of Representatives Debbie Dingell (D-MI), and John James (R-MI) for the Cancer Prevention Caucus, and in support of the National Cancer Prevention Workshop," said Less Cancer founder and president Bill Couzens.
  • This year's workshop has a focus on rural health access, and the social determinants around cancer prevention and access to screening and treatment.
  • We are excited by the experts, and the legislators who have joined us to support these efforts for cancer prevention."

ConcertAI Adds Healthtech Leader as Senior Vice President and General Manager of Digital Trial Solutions

Retrieved on: 
Wednesday, January 24, 2024
Senior, Philosophy, Form 1099, Patient, Research, Clinical trial, Software as a service, Full, Allegheny College, University, Business, Cancer, MBA, ERT, Generative, Psychology, Doctor of Philosophy, UPMC Hillman Cancer Center, Motivation, DTS, Nursing

CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, today announced that Ryan Kennedy has joined the company as Senior Vice President and General Manager of ConcertAI's Digital Trial Solutions™ (DTS) offering.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, today announced that Ryan Kennedy has joined the company as Senior Vice President and General Manager of ConcertAI's Digital Trial Solutions™ (DTS) offering.
  • Ryan brings over two decades of oncology clinical trials and clinical development industry experience in trial management and SaaS solutions.
  • He will lead the DTS business' Software-as-a-Service (SaaS) Suite, which is comprised of the Clinical Trial Optimization™ solution, DTS Patient-to-trial matching, and DTS Full eCRF automations.
  • "I am thrilled to join the ConcertAI team to help bring truly life-changing solutions to our sites, networks, and customers.

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Associa

Retrieved on: 
Tuesday, November 28, 2023
Plenary session, NPC, Food, Survival, Risk, ASCO, CHRS, HKEX, FDA, PD-1, Progression-free survival, Incidence, Society, Cisplatin, Cancer, UPMC Hillman Cancer Center, Annual general meeting, American Medical Association, Death, UPMC, Nature Medicine, Sun, EBV, Patient, OS, PFS, Journal, Development, PD-L1, GP, Pharmaceutical industry

REDWOOD CITY, Calif. And SHANGHAI, China, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180) announced today the publication of the final overall survival (OS) results from the pivotal JUPITER-02 study (NCT03581786), a randomized, double-blind, placebo-controlled, international, multi-center Phase 3 clinical trial evaluating the immune checkpoint inhibitor LOQTORZI™ (toripalimab-tpzi), in combination with the chemotherapy agents gemcitabine and cisplatin, as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) in the Journal of the American Medical Association (JAMA). As previously reported at the 2023 American Society of Clinical Oncologists (ASCO) Annual Meeting, the final analysis revealed a 37% reduction in the risk of death in NPC patients treated with toripalimab plus chemotherapy versus chemotherapy alone.

Key Points: 
  • Coherus plans to launch LOQTORZI in the United States in January 2024.
  • “There are limited options for patients living with this aggressive head and neck cancer.
  • The median OS was not reached in the LOQTORZI arm and was 33.7 months in the placebo arm.
  • The safety profile was consistent with that previously reported in other toripalimab clinical trials and consistent with the PD-1 inhibitor class.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Monday, October 30, 2023
AIM, NYSE, UPMC Hillman Cancer Center, IV, Therapy, Viral, Society for Immunotherapy of Cancer, DSM-IV codes, Cisplatin, MD, Research, University of Pittsburgh School of Medicine, SITC, Immunotherapy, Disease, COVID-19, Cancer, Annual general meeting, University, Society, Wilfrid Sellars, Patient, UPMC, Pharmaceutical industry

OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San Diego, CA and virtually.

Key Points: 
  • OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San Diego, CA and virtually.
  • The abstract concerns a Phase 2 single arm efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with AIM’s drug Ampligen and IV infusion of the checkpoint inhibitor pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.
  • The abstract authors include Robert Edwards, MD, Chief Medical Officer of the UPMC Community and Ambulatory Services Division and Co-Director of the Women’s Cancer Research Center at the UPMC Hillman Cancer Center.
  • Details for the presentation are as follows:

Integra Connect to Present Key Clinical Research at the ASCO Quality Care Symposium

Retrieved on: 
Tuesday, October 24, 2023
NSCLC, American Society of Clinical Oncology, III, Biomarker, Water Quality Initiative, UPMC Hillman Cancer Center, Health, Research, AM, Society, Multimedia, Integra, Quality of life, PALM, Medicine, Histology, Abstract, HRR, Immunotherapy, Oncology, Lung cancer, Cancer, Patient, UPMC, ASCO, Nursing, Pharmaceutical industry, Stonemasonry, Medical imaging, MD

WEST PALM BEACH, Fla., Oct. 24, 2023 /PRNewswire/ -- Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023. The findings from these three studies – two done in conjunction with UPMC Hillman Cancer Center in Pittsburgh, PA and one done in conjunction with South Carolina Oncology Associates (SCOA) – emphasize the critical role quality initiatives play in identifying gaps in care and driving action to improve patient outcomes. Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.

Key Points: 
  • , the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023.
  • Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.
  • The studies were conducted with Integra Connect as part of its Quality Initiatives program, which is designed to help oncology practices, cancer institutes, and health systems make well-informed clinical decisions to ensure patients are receiving the best possible care.
  • Integra Connect does this by bringing together clinical data from disparate systems and sources, organizing the information into complete, longitudinal patient journeys, and conducting in-depth analyses with its AI-enabled solutions.

CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release Syndrome in CAR T-cell Therapy

Retrieved on: 
Tuesday, October 17, 2023
Other Health, Research, General Health, Pharmaceutical, Oncology, Hospitals, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, UPMC Hillman Cancer Center, Incidence, MBA, Pharmacist, Doctor of Philosophy, MD, Safety, UPMC, Lymphoma, Cytokine release syndrome, CAR, Clinical trial, CRS, Patient, Toxic leukoencephalopathy, Pharmaceutical industry

The clinical trial will be conducted at multiple U.S. sites, with UPMC Hillman Cancer Center now the initial enrolling site.

Key Points: 
  • The clinical trial will be conducted at multiple U.S. sites, with UPMC Hillman Cancer Center now the initial enrolling site.
  • The trial investigates the safety, tolerability, and efficacy of different doses of CTO1681 in lymphoma patients receiving CAR T-cell therapy.
  • Certain advanced immunotherapies in the oncology space such as CAR T-cell and Bispecific Antibody Therapies suffer from high incidence of associated CRS.
  • We look forward to continued enrollment with data anticipated in 2024.”
    Details of the CTA-2101 trial can be found at www.clinicaltrials.gov under the identifier NCT05905328.

Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference

Retrieved on: 
Thursday, October 5, 2023
Recurrence, Conference, NYSE, UPMC Hillman Cancer Center, MS, Hereditary nonpolyposis colorectal cancer, Brain, Society, Brachytherapy, University, UPMC, Therapy, CATX, ASTRO, Neck, Lung, Head, Prostate cancer, Pelvic exenteration, Rate, Radiation, Patient, Medical imaging, MD

The first presentation, entitled “Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer,” was presented by Mohamed Abdelhakiem, MD from the UPMC Hillman Cancer Center in Pittsburgh, PA.

Key Points: 
  • The first presentation, entitled “Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer,” was presented by Mohamed Abdelhakiem, MD from the UPMC Hillman Cancer Center in Pittsburgh, PA.
  • The presentation described urinary data collected from 341 patients treated with Cesium-131 between 2006 and 2022.
  • The authors concluded that Cesium-131 brachytherapy is a promising alternative to pelvic exenteration, which can be a significant surgical procedure.
  • “We’re excited that UPMC’s long term data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ASTRO meeting,” said Thijs Spoor, Perspective’s Chief Executive Officer.